MacroGenics (NASDAQ: [[ticker:MGNX]]) says its chief medical officer, Jon Wigginton, will leave the Rockville, MD-based company as of March 27. The company said Wigginton, who joined MacroGenics in 2003, plans to resign “to pursue a new opportunity.” As MacroGenics, which is development antibody drugs for cancer, searches for a new CMO, its senior vice president of research and chief scientific officer, Ezio Bonvini, will head clinical development on an interim basis, according to a regulatory filing.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
